ArticleTranslational andrology and urology2026
Mixed epithelial and stromal tumor of the kidney: a case series of clinical diversity in atypical presentations.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study explores the clinicopathological features, diagnostic criteria, treatments, and prognosis of mixed epithelial and stromal tumor of the kidney (MESTK), with a focus on atypical cases (males and young females)-filling the gap in the perception that "only perimenopausal women are susceptible" in MESTK epidemiological data. Case Description: A retrospective analysis of 4 MESTK patients (admitted between January 2019 and December 2024) was conducted, including epidemiological data, imaging findings, pathology, immunohistochemistry (IHC), treatments, and follow-up outcomes. This analysis was combined with a literature review to summarize diagnostic and treatment patterns. Among the 4 patients, 3 were male (21, 29, and 54 years old) and 1 was female (22 years old). All were asymptomatic except 1, who reported occasional low back pain; the tumors were detected incidentally in all cases. Imaging showed cystic or cystic-solid masses (3 classified as Bosniak IIF; 1 with fat density). Pathologically, all tumors exhibited biphasic epithelial-stromal differentiation. Immunohistochemically, epithelial components expressed paired box gene 8 (Pax-8) and cytokeratin 7 (CK7); stromal components expressed estrogen receptor (ER) and progesterone receptor (PR). All patients underwent robot-assisted laparoscopic partial nephrectomy; postoperatively, physician assessment showed no significant decline in renal function, and patients reported no discomfort such as low back pain, with uneventful follow-ups. Conclusions: MESTK presents diverse clinical features, and male or young patients are not rare. Diagnosis requires integration of non-specific imaging findings with pathological and immunohistochemical examination (positive biphasic markers). Robot-assisted partial nephrectomy is effective, and benign cases have a good prognosis. This study enriches MESTK clinical data, aiding in the differentiation of atypical cases and providing clinical evidence for standardized diagnosis and minimally invasive treatment of such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.